Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.
Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L, Wandt H, Schäfer-Eckart K, Holowiecki J, Giebel S, Aschan J, Zander AR, Kröger N, Hilgendorf I, Baumgart J, Mylius HA, Pichlmeier U, Freund M. Casper J, et al. Among authors: volin l. J Clin Oncol. 2010 Jul 10;28(20):3344-51. doi: 10.1200/JCO.2009.23.3429. Epub 2010 May 24. J Clin Oncol. 2010. PMID: 20498405
Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation.
Casper J, Knauf W, Blau I, Ruutu T, Volin L, Wandt H, Schafer-Eckart K, Holowiecki J, Giebel S, Aschan J, Zander A, Kroger N, Doelken G, Freund M. Casper J, et al. Among authors: volin l. Ann Hematol. 2004;83 Suppl 1:S70-1. doi: 10.1007/s00277-004-0850-2. Ann Hematol. 2004. PMID: 15124679 Clinical Trial.
Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning.
Casper J, Holowiecki J, Trenschel R, Wandt H, Schaefer-Eckart K, Ruutu T, Volin L, Einsele H, Stuhler G, Uharek L, Blau I, Bornhaeuser M, Zander AR, Larsson K, Markiewicz M, Giebel S, Kruzel T, Mylius HA, Baumgart J, Pichlmeier U, Freund M, Beelen DW. Casper J, et al. Among authors: volin l. Bone Marrow Transplant. 2012 Sep;47(9):1171-7. doi: 10.1038/bmt.2011.242. Epub 2011 Dec 12. Bone Marrow Transplant. 2012. PMID: 22158386 Clinical Trial.
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.
Ruutu T, Volin L, Beelen DW, Trenschel R, Finke J, Schnitzler M, Holowiecki J, Giebel S, Markiewicz M, Uharek L, Blau IW, Kienast J, Stelljes M, Larsson K, Zander AR, Gramatzki M, Repp R, Einsele H, Stuhler G, Baumgart J, Mylius HA, Pichlmeier U, Freund M, Casper J. Ruutu T, et al. Among authors: volin l. Haematologica. 2011 Sep;96(9):1344-50. doi: 10.3324/haematol.2011.043810. Epub 2011 Jun 9. Haematologica. 2011. PMID: 21659356 Free PMC article. Clinical Trial.
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).
Kröger N, Iacobelli S, Franke GN, Platzbecker U, Uddin R, Hübel K, Scheid C, Weber T, Robin M, Stelljes M, Afanasyev B, Heim D, Deliliers GL, Onida F, Dreger P, Pini M, Guidi S, Volin L, Günther A, Bethge W, Poiré X, Kobbe G, van Os M, Brand R, de Witte T. Kröger N, et al. Among authors: volin l. J Clin Oncol. 2017 Jul 1;35(19):2157-2164. doi: 10.1200/JCO.2016.70.7349. Epub 2017 May 2. J Clin Oncol. 2017. PMID: 28463633 Free article. Clinical Trial.
Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma.
Schmidt-Hieber M, Blau IW, Trenschel R, Andreesen R, Stuhler G, Einsele H, Kanz L, Keilholz U, Marinets O, Beelen DW, Fauser AA, Volin L, Ruutu T, Uharek L, Fietz T, Knauf W, Hopfenmüller W, Thiel E, Freund M, Casper J. Schmidt-Hieber M, et al. Among authors: volin l. Bone Marrow Transplant. 2007 Apr;39(7):389-96. doi: 10.1038/sj.bmt.1705605. Epub 2007 Feb 19. Bone Marrow Transplant. 2007. PMID: 17310135
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socié G; ATG-Fresenius Trial Group. Finke J, et al. Among authors: volin l. Lancet Oncol. 2009 Sep;10(9):855-64. doi: 10.1016/S1470-2045(09)70225-6. Epub 2009 Aug 18. Lancet Oncol. 2009. PMID: 19695955 Clinical Trial.
Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial.
Finke J, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, Volin L, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Bertz H, Grishina O, Socié G; ATG-Fresenius Trial Group. Finke J, et al. Among authors: volin l. Biol Blood Marrow Transplant. 2012 Nov;18(11):1716-26. doi: 10.1016/j.bbmt.2012.06.001. Epub 2012 Jun 17. Biol Blood Marrow Transplant. 2012. PMID: 22713691 Free article. Clinical Trial.
CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT.
Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J, Socié G, Schwerdtfeger R, Kröger N, Ganser A, Niederwieser D, Polge E, Blau IW, Mohty M. Schmidt-Hieber M, et al. Among authors: volin l. Blood. 2013 Nov 7;122(19):3359-64. doi: 10.1182/blood-2013-05-499830. Epub 2013 Sep 13. Blood. 2013. PMID: 24037724 Free article.
234 results